Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Syndax: Q4 Earnings Snapshot AP - Thu Feb 26, 4:02PM CST

Syndax: Q4 Earnings Snapshot

SNDX : 24.16 (+1.17%)
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Feb 26, 3:01PM CST

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025...

SNDX : 24.16 (+1.17%)
Syndax Announces Participation in March Investor Conferences GlobeNewswire - Mon Feb 23, 6:00AM CST

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 24.16 (+1.17%)
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 GlobeNewswire - Thu Feb 19, 6:00AM CST

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 24.16 (+1.17%)
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit GlobeNewswire - Thu Feb 5, 6:00AM CST

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 24.16 (+1.17%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Wed Feb 4, 3:01PM CST

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February...

SNDX : 24.16 (+1.17%)
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Mon Jan 12, 6:00AM CST

 – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively –  – Continued acceleration in demand...

SNDX : 24.16 (+1.17%)
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. GlobeNewswire - Wed Jan 7, 6:00AM CST

- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast...

SNDX : 24.16 (+1.17%)
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Mon Jan 5, 6:00AM CST

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 24.16 (+1.17%)

Barchart Exclusives

As Dell Technologies Raises Its Dividend 20%, Should You Buy DELL Stock? Barchart - Tue Mar 10, 6:30PM CDT
With a 20% dividend hike, is Dell Technologies giving investors another reason to consider picking up its shares now? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot